Communiqués Compass Therapeutics, Inc.

Actions

CMPX

US20454B1044

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 15:49:30 01/10/2026			Varia. 5j.	Varia. 1 janv.
1,035 ^USD	-0,48 %		-7,49 %	-80,45 %

23/09	Les actions de Compass Therapeutics reculent après une dégradation de Wedbush	MT
23/09	Compass Therapeutics, Inc. : Wedbush neutre sur le dossier	ZM

Communiqués

22/09	Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback	AQ
06/08	Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update	AQ
17/07	Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026	AQ
30/06	A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs	AQ
28/05	Compass Therapeutics to Participate in Upcoming June Investor Events	AQ
21/05	Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting	AQ
12/05	Compass Therapeutics to Participate in Upcoming May Investor Events	AQ
05/05	Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update	AQ
27/04	Compass Therapeutics : 2026 Proxy	PU
27/04	Compass Therapeutics : Corporate Presentation	PU
27/04	Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer	AQ
27/04	Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer	AQ
24/04	Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer	AQ
05/03	Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update	AQ
06/01	Compass Therapeutics Provides Corporate Update	AQ
05/01	Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
05/01	Compass Therapeutics Announces Key Leadership Appointments	AQ
17/12	Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference	AQ
25/11	Compass Therapeutics to Participate in Upcoming December Investor Events	AQ
05/11	Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update	AQ
04/11	Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting	AQ
03/11	Compass Therapeutics to Participate in Upcoming November Investor Events	AQ
26/08/25	Compass Therapeutics to Participate in Upcoming September Investor Events	AQ
13/08/25	Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering	AQ
12/08/25	Compass Therapeutics Announces Proposed Public Offering	AQ